Median PFS in patients treated with temsirolimus/bevacizumab ( n = 400 ) versus IFN/bevacizumab ( n = 391 ) was 9.1 and 9.3 months , respectively ( hazard ratio [ HR ] , 1.1 ; 95 % CI , 0.9 to 1.3 ; P = .8 ) .